SynCardia 70cc TAH-t for Destination Therapy (DT)
Status unconfirmed · Not applicable
Conditions studied: Life-threatening, Biventricular Heart Failure, Ineligible for Cardiac Transplant
In brief
The SynCardia 70cc temporary Total Artificial Heart (TAH-t) is approved by the U.S. Food and Drug Administration (FDA) for use as a bridge to transplant for patients at risk of imminent (about to happen) death from irreversible biventricular heart failure. The purpose of this research study is to evaluate whether the TAH-t can support patients with life-threatening irreversible biventricular heart failure who are not eligible for transplantation. The TAH-t, when used for patients who are not eligible for transplant, is considered to be an investigational (not approved by FDA) use. This use is called destination therapy (DT). Nineteen (19) patients with life-threatening, biventricular failure who are not eligible for cardiac transplant will be enrolled in the Primary Arm of the study and followed for up to six months post-TAH-t implant. Safety will be evaluated by reviewing the adverse events that are experienced by the enrolled subjects and comparing them to previous experience of TAH-t patients who were waiting for a heart transplant. Since approximately 74% of patients with this condition would not be expected to live beyond six months, the benefit of the TAH-t for DT will be confirmed based on survival to six months without experiencing permanent disabling stroke-related deficits. After the six month follow-up visit, patients will continue to be followed under the study for up to five (5) years postTAH-t implant \[every six months for up to two years while supported with the TAH-t implant and then annually for another three years\]. Up to an additional 19 patients may be enrolled in the Secondary Arm of the study to further characterize the use of the TAH-t for DT in a broader patient population. Follow-up would be the same for patients enrolled in both arms of the study.
Key facts
- Study ID
- NCT02232659
- Run by
- SynCardia Systems. LLC
- People needed
- 38
- Starts
- 2016-02-01
- Expected to finish
- 2022-05-01
- Last updated by the study team
- 2021-03-17
Who can join
Age: 19 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients with ife-threatening, irreversible biventricular heart failure (Intermacs Patient Profile Classifications 1 - 4)
- Ineligible for cardiac transplantation (e.g., contraindication to immunosuppression, cancer, elevated panel reactive antibodies [PRAs]) as determined by the implanting center at time of implant screening assessment.
- On optimal medical management and failing to respond or failing DT VAD therapy (continuing to decline)
- Ambulatory without assistance
- Patients between 19 and 75 years of age
- Patients with Body Surface Area (BSA) of ≥ 1.7m2
- Sternum to T10 distance > 10cm OR adequate room in chest as determined by 3-D imaging assessment or by other standard clinical assessments
You may not qualify if…
- Cardiac transplant-eligible patients
- Patients who cannot be adequately anticoagulated on the TAH-t
- Patients with insufficient space in the chest
- Patients on ECMO support
- Patients with Cirrhosis (evidenced by ultrasound, CT scan, or positive biopsy)
- Patients with Acute or Chronic Renal dysfunction (per Intermacs AE Definitions)
- Patients with cardiac cachexia (e.g., pre-albumin <17, fragility, and catabolic/anabolic imbalance)
- Patients with a comorbidity that has a poor prognosis of survival beyond six months
- Patients with insufficient social support or who have demonstrated non-compliance with medical instructions (as determined by the Principal Investigator)
- Secondary Arm
- Inclusion Criteria:
- Patients who are NOT eligible to participate in the Primary Arm
- Patients with life-threatening, irreversible biventricular heart failure (Intermacs Patient Profile Classifications 1 - 7)
- Ineligible for cardiac transplantation (as determined by the implanting center at time of implant screening assessment).
- On optimal medical management and failing to respond or failing DT VAD therapy (continuing to decline)
- Patients 19 years of age or older
- Sternum to T10 distance > 10cm OR adequate room in chest as determined by 3-D imaging assessment or by other standard clinical assessments
- Exclusion Criteria:
- Patients who are less than 19 years old
- Cardiac transplant-eligible patients
- Patients with Cirrhosis (evidenced by ultrasound, CT scan, or positive biopsy)
- Patients with Chronic Renal dysfunction (per Intermacs AE Definitions)
- Patients with insufficient space in the chest
- Patients who cannot be adequately anticoagulated on the TAH-t
- Patients with insufficient social support or who have demonstrated non-compliance with medical instructions (as determined by the Principal Investigator)
Where it is running
- Banner University Medical Center Phoenix — Phoenix, Arizona, United States (enrolling)
- Banner University Medical Center — Tucson, Arizona, United States (enrolling)
- Cedars-Sinai Medical Center — Los Angeles, California, United States (enrolling)
- Integris Baptist Medical Center — Oklahoma City, Oklahoma, United States (enrolling)
- Memorial Hermann Hospital — Houston, Texas, United States (enrolling)
- Virginia Commonwealth University — Richmond, Virginia, United States (enrolling)
- Froedtert & the Medical College of Wisconsin — Milwaukee, Wisconsin, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.